Photocure fundamentale forhold (PHO)

Helt1 · desember 20, 2021, 9:18pm

Bull eller meh for PHO på kort sikt?

Fso · desember 20, 2021, 9:21pm

Vi ser hva market siger mandag imo Bull

rosk82 · desember 20, 2021, 9:30pm

Kan muligens trigge litt mer info om Cevira og Hexvix ifbm. Asieris.

Teddy1 · desember 20, 2021, 10:12pm

Utvilsomt positivt at asieris får inn kapital til å utvikle seg videre. Utvikling av legemidler(cevira), uvide salgsapparatet(hexvix) etc.

Om det slår ut på aksjekurs skal ikke jeg spå
Edit: det savepig sa.

Savepig · desember 20, 2021, 10:03pm

Tweeten er jo ukevis gammal.

Tekspert · januar 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (107 likes)

@Savepig (60 likes)

@OYV (57 likes)

Resten av topp 10:

@myk (46 likes)
@rosk82 (45 likes)
@CanonBoy (40 likes)
@h3nk1 (39 likes)
@Hayen (24 likes)
@Teiner (24 likes)
@Bonus (22 likes)

Gratulerer!

Fornybar · januar 1, 2022, 10:29am

Godt nyttår folkens.

Savepig · januar 1, 2022, 2:53pm

Ny kinesisk biotwitter, allerede fulgt av brad loncar

Fornybar · januar 2, 2022, 7:44am

Ny og ny? Registrerte seg januar 2020 og har 28 følgere. What is this

Andre10k · januar 3, 2022, 6:52am

PHO: STARTER KOMMERSIELT SALG AV CYSVIEW I CANADA

Oslo (Infront TDN Direkt): Photocure vil i dag starte salg, markedsføring og distribusjon av Cysview i Canada.

Det fremgår av en melding mandag.

–Vi er veldig glade for å integrere det kanadiske markedet inn i vårt amerikanske segment, hvilket vil utvide den direkte markedsmuligheten for Cysview med omtrent 10 prosent, sier Daniel Schneider administrerende direktør i selskapet.

Mari Nøvik mn@tdndirekt.com

Infront TDN Direkt, +47 21 95 60 71

ufo · januar 12, 2022, 5:27pm

https://journey.ct.events/view/6e58de92-4aeb-44d6-bb5c-f815d8e7928f

H.C. Wainwright BioConnect 2022 Virtual Conference

Veldig bra gjennomgang av dan schneider.

$$$$$$---- Snadder fra Schneider----$$$$$$

Det flere 10-årene gamle utstyret blir avløst av siste generasjons scope fra den tyske produsenten og kommer på markedet våren 22.

TekBot · januar 20, 2022, 7:57am

Major shareholder disclosure - Photocure ASA

Bonus · januar 22, 2022, 7:59pm

Intressang analyse som kom ut 24/12-2021 som også tar for seg historien til Photocure.
Den er på Svensk, og lesevendlig

Kan ikke se de har fått med noe kursmål, men en bra gjennomgang av selskapet.

Tekspert · februar 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (96 likes)

@Savepig (80 likes)

@myk (76 likes)

[quote=“myk, post:5300, topic:18877”]

Resten av topp 10:

@rosk82 (68 likes)
@OYV (46 likes)
@gabster (39 likes)
@CanonBoy (39 likes)
@Quadruple (34 likes)
@Snoeffelen (28 likes)
@HO5 (21 likes)

Gratulerer!

TekBot · februar 4, 2022, 7:12am

Photocure ASA – Major shareholding disclosure

TekBot · februar 7, 2022, 6:25am

Bladder Cancer technology: New improved Blue Light Cystoscopy system receives FDA approval for use in NMIBC in the U.S.

Oslo, Norway, February 7, 2022: Photocure ASA, The Bladder Cancer Company,
announces U.S. Food and Drug Administration (FDA) approval of a new and improved
Blue Light system to be used with Photocure’s Cysview[®] product in Blue Light
…

Vis børsmeldingen

Cystoscopy (BLC[®]) procedures for the detection of NMIBC*. Manufactured and
soon to be commercialized by KARL STORZ Endoscopy-America, Inc. (KARL STORZ),
the new Blue Light system is approved for use in procedures requiring rigid
cystoscopy. FDA approval was granted to KARL STORZ on February 4, 2022.

“The successful FDA approval is great news for the bladder cancer community in
the U.S.,” commented Geoffrey Coy, Vice President and General Manager, North
America at Photocure. “In healthcare, constant technical innovation is crucial,
and we expect that this new, enhanced BLC system will fulfill our clients’
expectations for improving the Blue Light experience. The new system is the next
generation and includes practical features to make the technology more user
friendly. We look forward to expanding the use of BLC with Cysview[®],” Geoffrey
Coy concluded.

“At KARL STORZ, we are committed to helping our customers deliver top-quality
care, and we believe that our new Blue Light system demonstrates this
commitment,” said Michael Lyman, Executive Director, Sales & Marketing, Urology
and Gynecology, KARL STORZ Endoscopy-America. “The New Blue Light Powered by
Saphira[®] will allow us to serve the needs of our customers, providing next
-level visualization to enable the right solutions for urological procedures in
patients with Non-Muscle Invasive Bladder Cancer and continue our collaboration
with the Photocure team to make high-quality BLC available to more patients in
the U.S.”.

Photocure expects to inform its stakeholders about the launch of the new Blue
Light system as KARL STORZ provides further information regarding the product
and its launch plans.

*NMIBC: non-muscle invasive bladder cancer

Note to editors

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA and KARL STORZ Endoscopy. Hexvix[®]/Cysview[®] and
BLC[®] are registered trademarks of Photocure ASA. Saphira[®] is a registered
trademark of KARL STORZ Endoscopy.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide, with 1 720 000
prevalent cases (5-year prevalence rate)[1a], 573 000 new cases and more than
200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview[ ]improves the detection of tumors and leads to more
complete resection, fewer residual tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, and New Zealand. Please refer to
Our Partners for further information on our
commercial partners.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

About KARL STORZ Endoscopy-America, Inc.

KARL STORZ Endoscopy-America, Inc., is an affiliate of KARL STORZ SE & Co. KG,
an international leader for more than 75 years in advanced medical technology,
providing surgical and procedural imaging, instrumentation, and enterprise-wide
integration. Based in Tuttlingen, Germany, KARL STORZ SE & Co. KG is a family
-owned company that designs, engineers, manufactures, and markets all its
products with an emphasis on visionary design, precision craftsmanship, and
clinical effectiveness. For more information, call (800) 421-0837 or visit the
company’s website at www.karlstorz.com.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

TekBot · februar 8, 2022, 2:08pm

Major shareholder disclosure in Photocure ASA

Bonus · februar 8, 2022, 2:21pm

TekBot · februar 11, 2022, 9:06am

Photocure Partner Asieris announces Approval to conduct a Phase III Clinical Trial for Hexvix in China

Oslo, Norway, February 11, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer
Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has
obtained the Phase III clinical trial application (CTA) approval from the
…

Vis børsmeldingen

National Medical Products Administration (NMPA) of China for Hexvix[®].

The study is a prospective, multicenter bridging trial aimed to investigate the
additional detection rate and safety of Hexvix[®] and blue light cystoscopy
(BLC[®]) versus white light cystoscopy in Chinese patients with non-muscle
invasive bladder cancer (NMIBC, tumor types CIS, Ta, T1). The study will be led
by Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
Professor Li Hanzhong, head of the Department of Surgery, Peking Union Medical
College Hospital, will serve as the Principal Investigator to lead a team of top
experts in the field of bladder cancer in China to carry out this study.

According to Frost & Sullivan, the number of new bladder cancer cases in China
reached 86,000 in 2020, and is expected to rise to 101,000 in 2025, with a
compound annual growth rate of 3.4% during the period. The total number of
patients with bladder cancer in China was estimated to be higher than 600,000 in
2020. The use of BLC with Hexvix for the management of NMIBC is included in the
global expert consensus guidelines.

In January 2021, Asieris Pharmaceuticals entered into a license agreement with
Photocure, obtaining exclusive rights to register and commercialize Hexvix in
mainland China and Taiwan. In December 2021, Hexvix was put into pilot use in
the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province:
the first patient in China received blue light cystoscopy with Hexvix at Hainan
General Hospital (404: Not found
-patient-procedure-with-hexvix-in-china-under-special-access-program-4149992).

“We are very glad that the phase ? trial of Hexvix has been approved by the
NMPA” said Dr. Yong Xue, Chief Medical Officer of Asieris. “We will accelerate
the clinical trial process so that doctors and patients in China will have
access to this breakthrough technology as early as possible.”

“This clinical registration trial is a critical step toward giving bladder
cancer patients access to Hexvix in China. Hexvix is a diagnostic agent that has
been proven to improve the detection, and completeness of resection of tumors,
and can be an important solution in the management of disease”, said Anders
Neijber, Vice President Global Medical Affairs and Clinical Development at
Photocure.

Read Asieris’ full media release here: https://asieris.com/asieris-announced
-hexvix-a-drug-for-diagnosis-of-bladder-cancer%ef%bf%bc-has-obtained-the-ind
-approval-from-the-nmpa-for-phase-%e2%85%b2-clinical-trial/

Note to editors

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide with 1 720 000
prevalent cases (5-year prevalence rate)[1a], 573 000 new cases and more than
200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview[ ]improves the detection of tumors and leads to more
complete resection, fewer residual tumors and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe, and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia and New Zealand. Please refer to
Our Partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

TekBot · februar 17, 2022, 9:07am

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2021 financial results

Oslo, Norway, 16 February 2022: Photocure ASA (Photocure, PHO: OSE) will
announce the fourth quarter and preliminary full year 2021 financial results on
Wednesday 23 February 2022 at 07:30 CET and invites investors, analysts and the
…

Vis børsmeldingen

media to a presentation at 14:00 CET the same day.

The investor presentation will be streamed live and be hosted by Daniel
Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and
questions can be submitted throughout the event.

The quarterly report and presentation will be published at 07:30 CET and will be
publicly available at www.photocure.com. The streaming event is available
through https://channel.royalcast.com/landingpage/hegnarmedia/20220223_10/

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway) Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde